Originally posted by the Voice of America.
Voice of America content is produced by the Voice of America,
a United States federal government-sponsored entity, and is in
the public domain.


Experimental Coronavirus Vaccines Continue to Show Promise in Human Trials

VOA News

   With over 14.7 million confirmed novel coronavirus cases and nearly
   610,000 fatalities, researchers are reporting progress in the race to
   develop a safe and effective vaccine against the disease.

   Two different experimental vaccines -- one developed in a joint venture
   between Britain's Oxford University and British-Swedishdrug
   makerAstraZeneca, the other by Chinese biotech firmCanSinoBiologics --
   have produced strong immune responses in late-stage human trials,
   according to two peer-reviewed studies published Monday in the British
   medical journalThe Lancet.

   Meanwhile, U.S. drug maker Pfizer and its German partnerBioNTechalso
   reported positive progress Monday on their vaccine candidate.

   The vaccine developed by the joint Oxford-AstraZeneca partnership is
   receiving the most attention, with the company having signed agreements
   with many governments to supply its vaccine if it is proved to be
   effective and granted regulatory approval. The company has already
   committed to making 2 billion doses.

   According toThe New York Times,the doses have been administered to more
   than 10,000 volunteers in Britain, Brazil and South Africa, with 30,000
   participants in the United States set to receive the experimental
   vaccine next week.

.